Canaccord analyst Edward Nash lowered the firm’s price target on Travere Therapeutics to $35 from $37 and keeps a Buy rating on the shares. The firm noted Travere announced that Mirum Pharmaceuticals will acquire rights and assets related to Travere’s two commercial bile acid products, Cholbam and Chenodal. Canaccord believes the deal is a positive for Travere as it now has its complete focus as a pure play kidney disease company.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on TVTX:
- Mirum to buy bile acid portfolio from Travere Therapeutics for $445M
- Travere to sell bile acid product portfolio for up to $445M to Mirum
- Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Travere Therapeutics Announces Presentations of Abstracts at the 60th European Renal Association (ERA) Congress 2023
- Travere Therapeutics to Present at Upcoming Investor Conferences